However, in early-stage HER2+ breast cancer, the 27-gene HER2DX genomic assay, which provides a pathological complete response (pCR) likelihood score and a risk score, has demonstrated both prognostic and predictive value12–19. Here, ERBB2 is linked to breast carcinoma.